Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Melanoma/Skin Cancers

Type: Oral Abstract Session

Time: Tuesday June 4, 9:45 AM to 12:45 PM

Location: S406

Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Sub-category:
Local-Regional

Category:
Melanoma/Skin Cancers

Meeting:
2019 ASCO Annual Meeting

Abstract No:
9503

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 9503)

Author(s): Alexander M. Menzies, Elisa A. Rozeman, Rodabe Navroze Amaria, Alexander Chan Chi Huang, Richard A. Scolyer, Michael T. Tetzlaff, Bart A. Van De Wiel, Serigne Lo, Ahmad A. Tarhini, Hussein Abdul-Hassan Tawbi, Elizabeth M. Burton, Giorgos Karakousis, Paolo Antonio Ascierto, Andrew Spillane, Michael A. Davies, Alexander Christopher Jonathan Van Akkooi, Tara C. Mitchell, Georgina V. Long, Jennifer Ann Wargo, Christian U. Blank, International Neoadjuvant Melanoma Consortium (INMC); Melanoma Institute Australia, University of Sydney, Royal North Shore Hospital, Sydney, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; The University of Texas - MD Anderson Cancer Center, Houston, TX; Univ of Pennsylvania, Bryn Mawr, PA; The University of Sydney, Melanoma Institute Australia and Royal Prince Alfred Hospital, Sydney, NSW, Australia; The University of Texas MD Anderson Cancer Center, Houston, TX; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Case Comprehensive Cancer Center/Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Istituto Nazionale dei Tumori IRCCS Fondazione, Naples, Italy; Melanoma Institute Australia, Sydney, Australia; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia

Abstract Disclosures

Abstract:

Background: Pathological complete response (pCR) to neoadjuvant systemic therapy (NST) correlates with survival, and is recognized as a path to regulatory approval in several cancers. Recent trials have reported that neoadjuvant immunotherapy (IT) and targeted therapy (TT) regimens achieve high pCR rates and impressive recurrence-free survival in stage III melanoma, however, the relationship between pCR, relapse-free (RFS) and overall survival (OS) in larger datasets of melanoma patients (pts) remains unknown. Methods: We pooled data from 6 modern NST clinical trials of anti-PD-1 based immunotherapy or BRAF/MEK targeted therapy conducted across institutions participating in the INMC. Pts with RECIST measurable, surgically resectable clinical stage III melanoma who underwent surgery were included. NST regimens included nivolumab (as monotherapy or in combination with ipilimumab), pembrolizumab or dabrafenib+trametinib. Baseline disease characteristics, treatment regimen, pCR and RFS were examined. Results: 184 pts with clinical stage III melanoma (AJCCv7: 100 IIIB, 84 IIIC) completed NST (133 IT, 51 TT) and underwent surgery. Median age was 57y (range 18-87). A pCR was observed in 41% of patients; 51 (38%) with IT and 24 (47%) with TT. Median follow-up post-surgery is 13 mo (95% CI 12-16); 10 mo with IT and 22 mo with TT. 44 (24%) pts have recurred (17 loco-regional, 21 distant, 6 both sites at first recurrence), 18 (14%) after IT and 26 (51%) after TT. 12-month RFS was improved with IT vs TT (83% vs 65%, p < 0.001). For those with pCR, 7% have recurred, 0/51 (0%) after IT, 7/17 (41%) after TT. For those without pCR, 34% have recurred, 18/82 (22%) after IT and 19/27 (70%) after TT. 12-month RFS was improved in those with pCR vs without pCR (95% vs 62%, p < 0.001), including in those with IT (100% vs 72%, p < 0.001) and TT (88% vs 43%, p < 0.001). 16 (9%) patients have died including two who had a pCR, both from TT. Conclusions: Neoadjuvant IT and TT are active regimens in resectable clinical stage III melanoma patients and are associated with high pCR rate. The ability to achieve pCR correlates with improved RFS and remarkably no patient with pCR from immunotherapy has recurred to date.

 
Other Abstracts in this Sub-Category:

 

1. A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9502 First Author: Carina N. Owen
Category: Melanoma/Skin Cancers - Local-Regional

 

2. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9582 First Author: Dirk Schadendorf
Category: Melanoma/Skin Cancers - Local-Regional

 

3. Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9583 First Author: Emilia Nan Tie
Category: Melanoma/Skin Cancers - Local-Regional

 

More...